Several studies have demonstrated that CDK4 is upregulated in cancer (28–33) and inhibiting CDK4 expression increases the efficacy of clinical treatments for breast cancer, melanoma, liposarcoma, and mantle cell lymphoma (34–37). This evidence concerns the gene CDK4 and liposarcoma.